INTRODUCTION {#s1}
============

*BRCA1* and *BRCA2* play pivotal roles in DNA homologous recombination repair (HRR), and germline *BRCA1/2* mutations reportedly increase risk of pancreatic ductal adenocarcinoma (PDAC). A large clinic-based cohort study enrolling 306 patients with PDAC reported the prevalence of pathogenic *BRCA1/2* germline mutations to be 4.6% \[[@R1]\]. Moreover, several retrospective studies have indicated that patients with PDAC harboring germline *BRCA1/2* mutations are more sensitive to platinum-based chemotherapy than those without the mutations \[[@R2]--[@R4]\].

In addition to *BRCA1/2*, other genes such as *ATM*, *ATR*, and *PALB2* are involved in HRR \[[@R5]\]. In ovarian cancer, both germline and somatic mutations in HRR-related genes are predictive of response to platinum-based chemotherapy \[[@R6]\]. Therefore, it is reasonable to speculate that patients with PDAC harboring mutations in HRR-related genes in their tumor tissues are sensitive to platinum-based chemotherapy. Supporting this idea, Waddell et al. reported that four of five patients with PDAC who were deficient in *BRCA1*/*2* or *PALB2* responded to platinum-based chemotherapy \[[@R7]\].

Oxaliplatin, a third-generation diaminocyclohexane platinum compound, is now commonly used in patients with PDAC \[[@R8]--[@R12]\]. However, to date, studies in patients with PDAC investigating prevalence of HRR-related gene mutations in tumor tissues and their association with efficacy of oxaliplatin-based chemotherapy are sparse. Therefore, we aimed to evaluate the association between HRR-related gene mutations identified using a Clinical Laboratory Improvement Amendment (CLIA)-certified multiplex next-generation sequencing (NGS) assay (OncoPrime^TM^) \[[@R13]\] and efficacy of oxaliplatin-based chemotherapy in patients with PDAC.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

Patient characteristics are summarized in Table [1](#T1){ref-type="table"}, and characteristics of individual patients are shown in Table [2](#T2){ref-type="table"}. The median age was 64 (range 39--81) years.

###### Patient characteristics

                                                          Number of Patients (%)            
  ------------------------------------ ------------------ ------------------------ -------- -----------
  Sex                                                                                       
                                       Male               7                        8        15 (53.6)
                                       Female             6                        7        13 (46.4)
  Age, years                                                                                
                                       Median             61                       64       64
                                       Range              44--81                   39--74   39--81
                                       Age ≤ 60 years     6                        6        12 (42.9)
  Disease status                                                                            
                                       Locally advanced   5                        2        7 (25.0)
                                       Metastatic         5                        6        11 (39.3)
                                       Recurrence         3                        7        10 (35.7)
  Family history of cancer                                                                  
                                       Yes                8                        9        17 (60.7)
                                       No                 3                        4        7 (25.0)
                                       Unknown            2                        2        4 (14.3)
  Family history of pancreatic caner                                                        
                                       Yes                1                        3        4 (14.3)
                                       No                 10                       10       20 (71.4)
                                       Unknown            2                        2        4 (14.3)
  Oxaliplatin-based chemotherapy                                                            
                                       Yes                8                        9        17 (60.7)
                                       No                 5                        6        11 (39.3)

###### Characteristics of individual patients

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Age   Sex   Family history of cancer                                           Disease status                  Oxaliplatin-based regimen   Identification of HRR-related gene mutations
  ------ ----- ----- ------------------------------------------------------------------ ------------------------------- --------------------------- ----------------------------------------------
  1      66    F     Unknown                                                            Metastatic                      FOLFIRINOX                  No

  2      52    F     Gastric cancer (FDR), Colorectal cancer (TDR), Lung cancer (TDR)   Metastatic                      FOLFIRINOX                  No

  3      42    M     Pancreatic cancer (SDR)                                            Locally advanced                SOX                         No

  4      64    M     None                                                               Locally advanced                GEMOX                       No

  5      39    F     Cutaneous cancer (FDR)\                                            Metastatic                      SOX                         No
                     Esophageal cancer (TRD)                                                                                                        

  6      64    M     None                                                               Recurrence after adjuvant S-1   SOX                         No

  7      74    F     Lung cancer (FDR)                                                  Recurrence after adjuvant S-1   SOX                         No

  8      65    M     Gastric cancer (FDR), Lung cancer (TDR)                            Metastatic                      SOX                         No

  9      66    F     Unknown                                                            Recurrence after adjuvant S-1   GEMOX                       No

  10     55    M     None                                                               Metastatic                      FOLFIRINOX                  Yes

  11     52    M     Brain tumor (FDR)\                                                 Locally advanced                FOLFIRINOX                  Yes
                     Prostate cancer (TRD)                                                                                                          

  12     68    M     Gastric cancer (FDR)                                               Metastatic                      FOLFIRINOX                  Yes

  13     47    M     Pancreatic cancer (FDR)                                            Metastatic                      GEMOX                       Yes

  14     44    M     None                                                               Recurrence after adjuvant S-1   SOX                         Yes

  15     65    F     Gastric cancer, Colorectal cancer (FDR)                            Metastatic                      FOLFOX                      Yes

  16     81    M     Unknown cancer (FDR)                                               Metastatic                      SOX                         Yes

  17     57    F     Gastric cancer (FDR)                                               Recurrence                      SOX                         Yes

  18     65    M     Biliary tract cancer (FDR)                                         Recurrence                      \-                          No

  19     45    M     None                                                               Metastatic                      \-                          No

  20     73    M     Colorectal cancer (FDR)                                            Recurrence after adjuvant S-1   \-                          No

  21     60    F     Pancreatic cancer (FDR)                                            Recurrence after adjuvant S-1   \-                          No

  22     59    F     Gastric cancer (SDR)\                                              Recurrence after adjuvant S-1   \-                          No
                     Pancreatic cancer (TDR)                                                                                                        

  23     67    M     None                                                               Recurrence                      \-                          No

  24     60    F     Unknown                                                            Recurrence after adjuvant S-1   \-                          Yes

  25     61    M     Breast cancer (FDR)                                                Locally advanced                \-                          Yes

  26     67    F     Gastric cancer (FDR)                                               Locally advanced                \-                          Yes

  27     77    F     Unknown                                                            Locally advanced                \-                          Yes

  28     74    F     None                                                               Locally advanced                \-                          Yes
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FDR, first-degree relative; SDR, second-degree relative; TDR, third-degree relative.

Completion rate of the NGS-based multiplex gene assay {#s2_2}
-----------------------------------------------------

The NGS-based multiplex gene assay was performed using archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (*n* = 21) or fresh frozen tumor tissues obtained from liver metastases (*n* = 5), primary sites (*n* = 3), and a lymph node metastasis (*n* = 1). The first NGS assay failed in four patients because of poor DNA quality, and a second assay was successfully completed in two patients using fresh frozen tissue obtained via fine-needle aspiration from a liver metastasis (*n* = 1) and a primary site (*n* = 1). The overall completion rate of the NGS assay was 93.3% (Figure [1](#F1){ref-type="fig"}).

![Success rate of multiplex next-generation sequencing (NGS) assay in 30 consecutive patients with pancreatic cancer](oncotarget-09-19817-g001){#F1}

Identification of non-synonymous mutations in HRR-related genes {#s2_3}
---------------------------------------------------------------

The identified HRR-related gene mutations and their corresponding ID, reported in the *Catalogue of Somatic Mutations in Cancer* (COSMIC) database and the reference single nucleotide polymorphism (rs) ID in dbSNP, are summarized in Table [3](#T3){ref-type="table"}. *BRCA2* was the most commonly mutated gene (*n* = 10), followed by *ATM* (*n* = 8), *BRCA1* (*n* = 2), *CHEK2* (*n* = 2), *ATR* (*n* = 1), and *PALB2* (*n* = 1). In total, non-synonymous HRR-related gene mutations were identified in 13 patients (46.4%). Germline allele frequency of each variant in the normal population as reported in the Exome Aggregation Consortium (<http://exac.broadinstitute.org/>) and Human Genetic Variation Database (<http://www.hgvd.genome.med.kyoto-u.ac.jp/>) are also summarized in Table [3](#T3){ref-type="table"}.

###### Identified HRR-related gene mutations

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case    Gene                     Mutation                 Function                COSMIC ID      dbSNP ID       Germline test   ExAC           ExAc\          HGVD
                                                                                                                                                 East Asian     
  ------- ------------------------ ------------------------ ----------------------- -------------- -------------- --------------- -------------- -------------- --------------
  10      ATR                      I774fs                   Inactivating mutation   1617015        Not reported   negative        Not reported   Not reported   Not reported

  ATM     L2005V                   VUS                      Not reported            Not reported   positive       Not reported    Not reported   Not reported   

  BRCA2   I1929V                   VUS                      Not reported            rs79538375     positive       9.6e-04         9.8e-03        Not reported   

  11      ATM                      R2034X                   Inactivating mutation   922732         rs532480170    \-              1.7e-05        0              Not reported

  ATM     L2426I                   VUS                      Not reported            Not reported   \-             Not reported    Not reported   Not reported   

  BRCA1   L52F                     VUS                      Not reported            rs80357084     \-             1.3e-04         1.8e-03        2.5e-03        

  12      BRCA2                    S1989fs                  Inactivating mutation   Not reported   rs80359552     \-              Not reported   Not reported   Not reported

  BRCA2   N2436I                   VUS                      Not reported            rs80358955     \-             8.2e-06         0              2.1e-03        

  CHEK2   R474C                    Inactivating mutation    Not reported            rs540635787    \-             8.8e-06         1.2e-04        Not reported   

  13      ATM                      R1618X                   Inactivating mutation   1350875        Not reported   positive        Not reported   Not reported   Not reported

  14      BRCA2                    Q3026X                   Inactivating mutation   3468418        rs80359159     \-              1.7e-05        0              Not reported

  15      ATM                      L1700fs                  Inactivating mutation   Not reported   Not reported   \-              Not reported   Not reported   Not reported

  16      PALB2                    splice site 3350+5G\>A   VUS                     Not reported   rs587782566    positive        Not reported   Not reported   Not reported

  BRCA2   A2351G                   VUS                      Not reported            rs80358932     positive       1.3e-04         1.7e-03        1.2e-03        

  17      BRCA1                    R1443X                   Inactivating mutation   979730         rs41293455     \-              1.6e-05        0              Not reported

  24      BRCA2                    S871X                    Inactivating mutation   Not reported   rs397507634    negative        Not reported   Not reported   Not reported

  BRCA2   splice site 7977-2A\>T   Inactivating mutation    Not reported            rs276174899    negative       Not reported    Not reported   Not reported   

  BRCA2   V2503I                   VUS                      Not reported            rs587782191    negative       8.2e-06         Not reported   4.2e-04        

  ATM     R2691C                   VUS                      922745                  rs531980488    negative       1.1e-04         7.0e-04        Not reported   

  25      ATM                      V1038X                   Inactivating mutation   Not reported   Not reported   \-              Not reported   Not reported   Not reported

  26      BRCA2                    R2318X                   Inactivating mutation   Not reported   rs80358920     \-              Not reported   Not reported   Not reported

  27      BRCA2                    I1929V                   VUS                     Not reported   rs79538375     \-              9.6e-04        9.8e-03        0.012

          ATM                      V2951I                   VUS                     Not reported   Not reported   \-              Not reported   Not reported   Not reported

  28      CHEK2                    splice site 1591-1G\>A   VUS                     Not reported   Not reported   \-              Not reported   Not reported   Not reported
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VUS, variant of unknown significance; ExAC, Exome Aggregation Consortium; HGVD, Human Genetic Variation Database.

Family history of cancer {#s2_4}
------------------------

Among the 28 patients evaluated, family history of any cancer and of pancreatic cancer within third-degree relatives was confirmed in 17 (60.7%) and four patients (14.3%), respectively. Of the 13 patients harboring HRR-related gene mutations, only one had a family history of pancreatic cancer (Table [1](#T1){ref-type="table"}).

Efficacy of oxaliplatin-based chemotherapy {#s2_5}
------------------------------------------

Of the 28 patients evaluated, 17 received oxaliplatin-based chemotherapy. Treatment regimens are summarized in Table [2](#T2){ref-type="table"}. Three radiologic responses and one tumor marker response (CA 19-9 and CEA decrease *\>* 60%) were observed in patients harboring HRR-related gene mutations while only one radiologic response was observed in those without such mutations. Progression-free survival (PFS) and survival time after progression in individual patients are shown in Figure [2](#F2){ref-type="fig"}. Median PFS was significantly longer in patients with HRR-related gene mutations than those without mutations (20.8 months vs. 1.7 months, respectively; *p* = 0.049, Figure [3](#F3){ref-type="fig"}) and hazard ratio (HR) was 0.32 (95% confidence interval (CI), 0.10--1.06, *p* = 0.061).

![Progression-free survival, survival time after progression, and the response of individual patients who received oxaliplatin-based chemotherapy](oncotarget-09-19817-g002){#F2}

![Kaplan--Meier estimates of progression-free survival in patients who received oxaliplatin-based chemotherapy](oncotarget-09-19817-g003){#F3}

DISCUSSION {#s3}
==========

In this study, non-synonymous HRR-related gene mutations were identified in 13 (46.4%) of 28 consecutive patients with PDAC who were evaluated using an NGS-based multiplex gene assay covering complete coding exons of 12 HRR-related genes. Among the 13 patients with HRR-related gene mutations, only one (7.6%) had a family history of pancreatic cancer (Table [2](#T2){ref-type="table"}). In line with our current results, Shindo et al. recently reported that among 27 patients with pancreatic cancer harboring pathogenic germline mutations in *BRCA1*/*BRCA2*/*ATM*/*PALB2*, only three patients (11.1%) had a family history of pancreatic cancer \[[@R14]\]. These data suggest that prevalence of HRR-related gene mutations is not uncommon, even if a patient has no family history of pancreatic cancer.

Efficacy of oxaliplatin-based chemotherapies such as FOLFIRINOX, FOLFOX, GEMOX, and SOX in pancreatic cancer has been tested in several clinical trials \[[@R8], [@R9], [@R11], [@R12]\]. Among these, only FOLFIRINOX exhibited clear significant benefit over gemcitabine monotherapy (control) in a large randomized clinical trial and has been recommended for a standard treatment regimen \[[@R8]\]. Conversely, SOX failed to exhibit benefit over S-1 monotherapy in a second-line setting in a randomized clinical trial and is not recommended as standard treatment in routine clinical practice \[[@R11]\]. However, in this study, we observed one patient with an inactivating HRR-related gene mutation (*BRCA2* Q3026X) who did not respond to the standard chemotherapy of gemcitabine/nab-paclitaxel but exhibited a partial response to SOX (Figure [2](#F2){ref-type="fig"}, Case 14). These results suggested that an oxaliplatin-based regimen, which failed to demonstrate a positive result in a clinical trial involving random patients with PDAC, is still beneficial in patients harboring HRR-related gene mutations.

Among 28 patients, 17 received oxaliplatin-based chemotherapy. In total, three of eight patients who harbored HRR-related gene mutations showed a radiologic response to oxaliplatin-based chemotherapy and one showed a CA19-9 and CEA decrease of *\>* 60% at 8 weeks, which has been shown to be a predictor of better overall survival \[[@R15]\], whereas the response rate was 11.1% (1/9) among patients without such mutations. Interestingly, two patients with HRR-related gene mutations who received FOLFIRINOX as first-line treatment showed exceptional PFS responses for *\>* 24 months (Figure [2](#F2){ref-type="fig"}, Cases 10 and 11). Because impaired HRR may confer sensitivity to platinum agents and topoisomerase inhibitors \[[@R5], [@R16], [@R17]\], patients with HRR-related gene mutations may experience greater benefit from FOLFIRINOX treatment.

On the other hand, four patients with HRR-related gene mutations showed neither radiologic nor tumor marker response to oxaliplatin-based chemotherapy. One patient (Case 13) refused to continue chemotherapy after the first cycle of GEMOX due to its toxicity. The other three patients (Case 15, 16, 17), received oxaliplatin-based chemotherapy as third or later line treatment and this might have influenced the poor response. For example, Case 15 was obliged to discontinue chemotherapy after the first cycle of FOLFOX due to rapid deterioration of uncontrollable ascites. Therefore, to derive maximum benefit from oxaliplatin-based chemotherapy in patients with HRR-related gene mutations, it appears to be relevant to attempt this regimen at an earlier treatment time-point under better patient general status.

Pathogenic germline *BRCA1/2* mutations are listed among the genes recommended for reporting of secondary findings by the American College of Medical Genetics and Genomics (ACMG) \[[@R18]\], and we follow this recommendation in daily clinical practice. In this study, suspected pathogenic germline *BRCA1/2* mutations that met the ACMG recommendations were found in five patients (Table [3](#T3){ref-type="table"}, Cases 12, 14, 17, 24, and 26). However, except for case 24, four patients did not undergo the germline test primarily because the test results would not affect their own cancer treatment. We were able to conduct the additional germline DNA test in four patients who provided informed consent, and five of 10 HRR-related mutations were confirmed to be germline mutations (Table [3](#T3){ref-type="table"}).

Limitations of this study included a limited sample size, and differences in lines of treatment and oxaliplatin-based chemotherapy regimens among the patients. In addition, we could not eliminate the possibility that mutations identified in nine patients who did not undergo the germline test may have been derived from germline DNA.

In summary, the status of HRR-related gene mutations was positively associated with oxaliplatin-based chemotherapy in patients with PDAC. Monitoring HRR-related genes using an NGS assay might be useful in selecting PDAC patients potentially sensitive to oxaliplatin-based chemotherapy. We are currently planning a prospective trial to verify the results reported here and further explore precision medicine in the field of pancreatic cancer.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

A total of 30 consecutive patients with histologically confirmed PDAC who underwent an NGS-based multiplex assay (OncoPrime^TM^) at Kyoto University Hospital between April 2015 and July 2017 were eligible for this study.

NGS-based multiplex assay (OncoPrime^TM^) {#s4_2}
-----------------------------------------

An NGS-based multiplex assay (OncoPrime^TM^) covers complete coding exons of 215 cancer-related genes and rearrangements in 17 frequently rearranged genes ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R13], [@R19]\]. DNA extracted from archived FFPE tissue samples or fresh frozen tissue samples was used for this assay. NGS was performed in a CLIA-certified laboratory using Illumina HiSeq 2500 by EA Genomics (Morrisville, North Carolina, United States).

Identification of HRR-related gene mutations {#s4_3}
--------------------------------------------

Twelve HRR-related genes included in OncoPrime^TM^ (*ATM*, *ATR*, *BAP1*, *BRCA1*, *BRCA2*, *BLM*, *CHEK1*, *CHEK2*, *FANCA*, *MRE11A*, *PALB2*, and *RAD51*) were evaluated in this study. Variant calling was performed using variant calling software (VarPROWL) in a CLIA-certified laboratory by EA Genomics as previously reported \[[@R13]\] based on the following workflow:

Step 1: Remove all silent mutations in non-reference alleles, retaining mutations that are missense, are nonsense, or involve splicing junctions.

Step 2: Remove all non-reference alleles that appear in *\>* 1% of the population (high minor allele frequency) because they are likely germline events.

Step 3: Remove all non-reference alleles with allele frequencies of *\<* 4% and *\>* 95%. This was performed because the limit of detection was 4% and alleles with \> 95% frequency were most likely germline DNA because the sample material had at least 20% tumor content.

Step 4: The identified mutations were prioritized based on their presence in the following databases: Online Mendelian Inheritance in Man (<https://www.omim.org/>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), Clinical [Trials.gov](http://Trials.gov) (<https://clinicaltrials.gov/>), Drug Bank (<https://www.drugbank.ca/>), COSMIC (<http://cancer.sanger.ac.uk/cosmic>), and the Cancer Genome Atlas (<https://cancergenome.nih.gov/>).

After the filtering process mentioned above, non-synonymous mutations including variants of unknown significance were considered HRR-related gene mutations.

Efficacy of oxaliplatin-based chemotherapy {#s4_4}
------------------------------------------

Oxaliplatin-based chemotherapy includes oxaliplatin, irinotecan, fluorouracil, and *l*-leucovorin (FOLFIRINOX); gemcitabine and oxaliplatin (GEMOX); and S-1 and oxaliplatin (SOX) \[[@R8], [@R11], [@R12]\]. Standard doses and schedules of the regimens were adjusted at the discretion of the treating physicians based on incidence of adverse events and individual patient general status. Clinical data were retrieved using a prospective cohort database system (CyberOncology^®^; Cyber Laboratory Inc., Tokyo, Japan) and electronic medical records.

Statistical analysis {#s4_5}
--------------------

Objective response was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 \[[@R20]\]. PFS was defined as the interval between date of initiation of oxaliplatin-based chemotherapy and date of disease progression or death due to any cause. Survival time after disease progression was defined as the interval between date of disease progression and death. Patients not experiencing disease progression or death were censored at the last follow-up visit. Median PFS was estimated using the Kaplan-Meier method, and differences were compared using the log-rank test. The hazard ratio and 95% confidence interval were calculated using Cox regression models. The data cutoff date was November 30, 2017. Statistical analyses were performed using R version 3.4.1.

Ethics {#s4_6}
------

This study was approved by the Ethics Committee of Kyoto University Graduate School of Medicine (G692) and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for the use of genomic and clinical data for research purposes.
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